ALISO VIEJO, Calif., Nov. 7, 2014 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCBB:CNSO)
The House Veterans Affairs Subcommittee on Health has invited CNS Response Chairman Tom Tierney and CEO George Carpenter to submit testimony on November 19, 2014 for hearing in consideration of HR 5059, the Clay Hunt Suicide Prevention Act. At that time, the Company will provide detailed updates on the following items:
Walter Reed PEER Trial
The Walter Reed CNS Response PEER Trial is designed to follow up to 2,000 soldiers, and the protocol provides for interim reporting of results at 10%, 25% and 50% of planned study enrollment. The trial has been conducted under a public-private partnership with Walter Reed National Military Medical Center.
New patient recruiting for the trial was halted six months ago, although current patients continue in the Study and are being followed. Walter Reed leadership has notified the Company that it has concluded its internal review and will recommence recruiting for this trial following approval of a revised and updated protocol to its Institutional Review Board.
Results of the trial thus far have been consistent with previous clinical trials, and will be abstracted in the testimony. Based on these results and our experience working with VA/DOD, CNS Response will provide our recommendations with respect to the key legislative provisions of HR 5059.
The Department of Defense has made reduction of preventable error a priority throughout the military care system, with metrics due by the end of 2014. Quality assurance tools like PEER offer the opportunity to immediately improve the performance of existing therapies, improving access and outcomes for service members.
Evidence Milestones
The PEER Registry will soon pass the 10,000 unique patient mark — representing the largest clinical outcome database available to clinicians to guide treatment. We are grateful to the many patients and physicians who have participated in the research and outcomes reporting that have built this important evidence base.
Additionally, a number of independent clinical trials using quantitative EEG have recently been reported, adding to the growing evidence base for PEER. There are now 98 confirming studies of EEG-guided pharmacotherapy available for review at www.peerdossier.com.
About CNS Response Inc.
CNS Response (www.cnsresponse.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 37,350 outcomes for over 9,900 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response representatives at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.